Phibro Animal Health Q1 net sales rise 13% to $260.4 million; updates guidance
Phibro Animal Health reported fiscal first-quarter results for the period ended September 30, 2024, with net sales up 13% to $260.4 million and net income of $7.0 million, compared with a net loss of $8.0 million a year earlier. The company also updated its fiscal 2025 guidance, which excludes the pending Zoetis Medicated Feed Additive acquisition, and shareholders re-elected two directors and ratified PricewaterhouseCoopers as auditor at the November 5 annual meeting.
Key points
- Net income of $7.0 million, or $0.17 per diluted share, versus a net loss of $8.0 million in the year-earlier quarter
- Adjusted EBITDA of $30.7 million, up 64% from $18.7 million
- Fiscal 2025 guidance: net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million, excluding the Zoetis portfolio
- At the November 5, 2024 annual meeting, Mary Lou Malanoski and Carol A Wrenn were elected as Class II directors and PwC was ratified for fiscal 2025
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.